Jacques Izopet to Viral Load
This is a "connection" page, showing publications Jacques Izopet has written about Viral Load.
Connection Strength
0.602
-
Performance of a commercial assay for detecting and quantifying HEV RNA in faeces. J Clin Virol. 2018 12; 109:1-5.
Score: 0.171
-
Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies. Clin Infect Dis. 2018 11 28; 67(12):1883-1889.
Score: 0.043
-
A European multicenter study on the analytical performance of the VERIS HBV assay. J Clin Virol. 2018 Feb - Mar; 99-100:50-56.
Score: 0.040
-
A European multicientre study on the comparison of HBV viral loads between VERIS HBV assay and Roche COBAS® TAQMAN® HBV test, Abbott RealTime HBV assay, Siemens VERSANT HBV assay, and Qiagen artus HBV RG kit. J Clin Virol. 2017 10; 95:76-83.
Score: 0.040
-
HEV and transfusion-recipient risk. Transfus Clin Biol. 2017 Sep; 24(3):176-181.
Score: 0.039
-
Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study. J Antimicrob Chemother. 2017 06 01; 72(6):1769-1773.
Score: 0.039
-
Zika Virus Infection and Prolonged Viremia in Whole-Blood Specimens. Emerg Infect Dis. 2017 05; 23(5):863-865.
Score: 0.039
-
A European multicientre study on the comparison of HIV-1 viral loads between VERIS HIV-1 Assay and Roche COBAS® TAQMAN® HIV-1 test, Abbott RealTime HIV-1 Assay, and Siemens VERSANT HIV-1 Assay. J Clin Virol. 2017 07; 92:75-82.
Score: 0.039
-
A European multicentre study on the comparison of HCV viral loads between VERIS HCV assay and COBAS® TaqMan® HCV Test and RealTime HCV Assay. J Clin Virol. 2017 05; 90:18-25.
Score: 0.038
-
Hepatitis E Virus Infection in Solid Organ Transplant Recipients, France. Emerg Infect Dis. 2017 02; 23(2):353-356.
Score: 0.038
-
European Multicenter Study on Analytical Performance of DxN Veris System HCV Assay. J Clin Microbiol. 2017 04; 55(4):1186-1192.
Score: 0.038
-
Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen. Clin Infect Dis. 2018 05 02; 66(10):1588-1594.
Score: 0.010
-
Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial. J Antimicrob Chemother. 2018 03 01; 73(3):738-747.
Score: 0.010
-
Baseline and post-treatment hepatitis C NS5A resistance in relapsed patients from a multicentric real-life cohort. Antivir Ther. 2018; 23(4):307-314.
Score: 0.010
-
Antiviral effect of maraviroc in semen: a case report. Antivir Ther. 2012; 17(5):933-6.
Score: 0.007